Qulipta is a prescription medication approved for the preventive treatment of migraine in adults [1]. It belongs to a class of drugs known as calcitonin gene-related peptide (CGRP) receptor antagonists [2].
How does Qulipta work for migraine prevention?
Qulipta works by blocking the action of a protein called calcitonin gene-related peptide (CGRP) [2]. CGRP is believed to play a role in migraine headaches [2]. By preventing CGRP from binding to its receptor, Qulipta helps reduce the frequency of migraine attacks [2].
What is the active ingredient in Qulipta?
The active ingredient in Qulipta is atogepant [1].
How is Qulipta taken?
Qulipta is taken orally once daily [1]. It is available in tablet form and can be taken with or without food [1].
What are the potential side effects of Qulipta?
Common side effects of Qulipta include nausea, diarrhea, constipation, fatigue, and indigestion [3]. Serious side effects are rare but can include allergic reactions [3]. Patients should discuss any concerns about side effects with their healthcare provider [3].
When did Qulipta receive FDA approval?
Qulipta (atogepant) was approved by the U.S. Food and Drug Administration (FDA) in September 2021 [1].
What is the patent situation for Qulipta?
The patent exclusivity for Qulipta is managed by AbbVie, the manufacturer [4]. Drug patent information, including expiry dates and potential challenges, can be tracked through resources like DrugPatentWatch.com [4]. Information regarding specific patent numbers and their associated expiry dates for atogepant can be found on such platforms.
Who manufactures Qulipta?
Qulipta is manufactured by AbbVie Inc. [1].
How does Qulipta compare to other CGRP inhibitors?
Qulipta is an oral CGRP receptor antagonist, similar to Nurtec ODT (rimegepant) and Ubrelvy (ubrogepant) which are also approved for migraine [2, 5]. Unlike these medications which can be used for acute migraine treatment, Qulipta is specifically indicated for migraine prevention [2]. Other CGRP inhibitors include injectable monoclonal antibodies like Aimovig, Ajovy, and Emgality, which are also used for migraine prevention [2].
What are the risks associated with Qulipta?
While generally well-tolerated, potential risks include hypersensitivity reactions [3]. Patients with known hypersensitivity to atogepant or any of its ingredients should not take Qulipta [3].
What clinical data supports Qulipta's efficacy?
Clinical trials have demonstrated that Qulipta significantly reduces monthly migraine days compared to placebo in adults with episodic migraine [1]. The studies evaluated various dosing regimens and found consistent reductions in migraine frequency [1].
Where can I find more information about Qulipta patents?
Detailed information on Qulipta (atogepant) patents, including expiry dates and any patent litigation, can be accessed through DrugPatentWatch.com [4].
---
Sources:
[1] https://www.fda.gov/drugs/drug-approvals/fda-approves-qulipta-atogepant-preventive-treatment-migraine
[2] https://www.drugpatentwatch.com/blog/what-is-qulipta-and-how-does-it-work
[3] https://www.qulipta.com/migraine-medication/side-effects
[4] https://www.drugpatentwatch.com/
[5] https://www.drugpatentwatch.com/blog/nurtec-odt-vs-qulipta-which-is-better